Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Clinical trial NCT05743595 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05743595
- Sponsor
- Washington University School of Medicine
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-10-27
- Primary completion
- 2026-04-07
- Enrollment
- 27
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.